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An epigenomic roadmap to induced pluripotency
reveals DNA methylation as a reprogramming
modulator
Dong-Sung Lee1,2,3,*, Jong-Yeon Shin1,4,*, Peter D. Tonge5, Mira C. Puri5,6, Seungbok Lee1,2,3, Hansoo Park1,2,3,
Won-Chul Lee1,4, Samer M.I. Hussein5, Thomas Bleazard7, Ji-Young Yun1,4, Jihye Kim1,4, Mira Li5,
Nicole Cloonan8,9, David Wood8, Jennifer L. Clancy10, Rowland Mosbergen11, Jae-Hyuk Yi1, Kap-Seok Yang4,
Hyungtae Kim4, Hwanseok Rhee12, Christine A. Wells11,13, Thomas Preiss10,14, Sean M. Grimmond8,15,
Ian M. Rogers5,16,17, Andras Nagy5,17,18 & Jeong-Sun Seo1,2,3,4
Reprogramming of somatic cells to induced pluripotent stem cells involves a dynamic
rearrangement of the epigenetic landscape. To characterize this epigenomic roadmap, we
have performed MethylC-seq, ChIP-seq (H3K4/K27/K36me3) and RNA-Seq on samples
taken at several time points during murine secondary reprogramming as part of Project
Grandiose. We ﬁnd that DNA methylation gain during reprogramming occurs gradually, while
loss is achieved only at the ESC-like state. Binding sites of activated factors exhibit focal
demethylation during reprogramming, while ESC-like pluripotent cells are distinguished
by extension of demethylation to the wider neighbourhood. We observed that genes with
CpG-rich promoters demonstrate stable low methylation and strong engagement of histone
marks, whereas genes with CpG-poor promoters are safeguarded by methylation. Such DNA
methylation-driven control is the key to the regulation of ESC-pluripotency genes, including
Dppa4, Dppa5a and Esrrb. These results reveal the crucial role that DNA methylation plays as
an epigenetic switch driving somatic cells to pluripotency.
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S
omatic cells can be reprogrammed into induced pluripotent
stem cells (iPSCs) by the expression of deﬁned transcription
factors1–5. During the reprogramming process, the global
epigenetic landscape has to be reset to establish the epigenetic
marks of the pluripotent state through DNA methylation and
chromatin-remodelling processes2,6–9. Through the development
of a secondary reprogramming system10, iPSC generation was
initially described as a multistep process characterized by
transcriptional, DNA methylation and chromatin changes11–14.
Genome-wide analysis of speciﬁc chromatin modiﬁcation
dynamics at early stages of reprogramming indicated that this
progress might be constrained by repressive epigenetic modi-
ﬁcations, such as H3K9me3 and DNA methylation15–18.
More recently, it has been proposed that DNA methylation
during iPSC generation functions in the silencing of genes
involved in differentiation, while also facilitating chromatin
remodelling18–20. DNA demethylation appears to play an
important role in reactivating pluripotency genes, which are
hypermethylated and silenced in somatic cells, particularly in the
late stages of the reprogramming process13. However, overall
understanding of the global dynamics of epigenetic modiﬁcation
at different stages during reprogramming remains poor.
In this work, we have utilized a murine secondary
reprogramming system to sample cellular trajectories during
reprogramming and performed whole-genome bisulﬁte sequen-
cing, chromatin immunoprecipitation sequencing (ChIP-seq;
H3K4me3, H3K27me3 and H3K36me3), and RNA sequencing
(RNA-Seq) to characterize the epigenomic roadmap to pluripo-
tency at base resolution21,22. Our observations provide a deeper
understanding of the reprogramming process and reveal the
crucial role that DNA methylation plays in the epigenetic switch
that drives somatic cells to pluripotency.
Results and Discussion
Dynamic changes in DNA methylation during reprogramming.
The Project Grandiose secondary reprogramming samples
present a unique opportunity to proﬁle cellular state changes
at various time points during reprogramming10,21,22. These
consisted of secondary mouse embryonic ﬁbroblasts (2MEF),
six intermediate time points at high doxycycline (dox)
concentrations (D2H, D5H, D8H, D11H, D16H and D18H),
three alternative intermediate time points collected for samples
treated with reduced dox concentrations (D16L, D21L
and D21Ø), the secondary iPSCs (2iPSCs), the primary iPSCs
(1iPSCs) used to generate the chimeric mouse and a mouse
Rosa rtTA embryonic stem cell line (ESC) for standard
comparison (Fig. 1a–c). As described in ref. 21, these samples
showed reprogramming to two distinct pluripotent states:
ESC-like cells and the ‘F-class’ consisting of stages D16H
and D18H.
In this manuscript, we describe base-resolution bisulﬁte
sequencing of the 13 Project Grandiose samples and investigation
of global DNA methylation changes during reprogramming
(Supplementary Data 1). The sample methylomes were scanned
using a sliding window of 30 CpGs, identifying 7,890 differen-
tially methylated regions (DMRs) covering 22Mb, representing
0.81% of the mouse genome (Fig. 2a,b, Supplementary Data 2,
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Supplementary Figs 1a–c, 6a). Unsupervised hierarchical cluster-
ing performed on the DNA methylation state of DMRs (Fig. 2a)
distinguished the intermediate states (D2H-D18H and D16L-
D21L) from the ESC-like pluripotent states (D21Ø, 1oiPSCs,
2oiPSCs and ESCs). DMRs were categorized into three groups
based on the changing pattern of DNA methylation (Fig. 2a).
The DMR-1 group exhibited increased methylation levels after
(DMR-1a) or during (DMR-1b) high-level reprogramming factor
expression and included genes related to development and cell
differentiation, such as the Hox family, Col25a1 and Meox2. The
DMR-2 group represented differential methylation changes
between two pluripotent states: either gradual demethylation to
F-class and methylation in the ESC-like state (DMR-2a) or
gradual methylation to F-class and acquired demethylation in the
ESC-like state (DMR-2b). A ﬁnal group (DMR-3) was identiﬁed
as exhibiting low methylation levels in the ESC-like state
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Figure 2 | DMRs and features affecting DNA methylation change during reprogramming. (a) Hierarchical clustering based on the DNA methylation level
of DMRs in each sample. Each DMR was centred with the mean and normalized. DMRs were clustered into six groups based on pairwise correlations.
(b) Base-level visualization of two DMRs from group DMR-3b in the promoter regions of Dppa4 and Dppa2, known ESC-pluripotency predictor genes.
(c) DMR accumulation during reprogramming. DMRs were deﬁned as hyper- and hypo-DMRs at each time point. Dark red and dark blue bars represent
ESC-speciﬁc Hyper- and Hypo-DMRs. Other colours indicate Hyper- and Hypo-DMRs in the order of left to right. (d) Proportion of DMRs containing
various genomic features. (e) Fold enrichment of examined genomic features within DMRs. (f) Percentage of DMRs containing H3K4me3 or H3K27me3
based on the methylation level (low-methylated r30%, high-methylated Z70%).
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(1iPSCs, 2iPSCs and ESCs), with stable methylation persisting
in the F-class state and intermediate reprogramming samples,
which included multiple pluripotency genes such as Dppa2,
Dppa4, Dppa5a, Esrrb, Tcl1 and Eras (Fig. 2a, Supplementary
Data 2).
We annotated the DMRs in each sample as Hyper- or Hypo-
DMRs where they differed from a corresponding 2MEF baseline
by over 20% (Fig. 2c). We observed a widespread gradual increase
in methylation to generate Hyper-DMRs during reprogramming,
whereas limited demethylation was observed as cells repro-
grammed to the F-class state (D16H and D18H). The steady
increase in Hyper-DMRs during both high-dox and low-dox
reprogramming challenges the notion that most changes in DNA
methylation occur at a late stage when cells acquire stable
pluripotency13. A similar trend was observed for the average
methylation level of DMRs, as methylation occurred gradually,
while demethylation did not change signiﬁcantly during
transgene expression (Supplementary Fig. 2a,b). Almost all
Hypo-DMRs found in iPSCs were also observed in ESCs
(98.94%); however, this was not the case for Hyper-DMRs
(61.88%), suggesting that demethylation during reprogramming
occurred more conservatively.
Table 1 | Enrichment of TFBSs in each DMR group.
DMR groups DMR
Number
Sequence-speciﬁc transcription factors Transcription regulators
TET1 CTCF Oct4 SOX2 NANOG ESRRB ZFX KLF4 cMYC nMYC E2F1 TCFCP2L1 SMAD1 STAT3 p300 EZH2 SUZ12 RING1B
DMR-1
1a 1,819 NE NE              NE NE NE
1b 1,453 NE NE              þ þ þ þ þ
DMR-2
2a 553 NE NE  NE NE NE NE þ þ NE NE NE NE NE NE    
2b 1,291 þ NE NE NE NE þ þ þ NE NE þ NE þ  NE þ þ þ þ þ þ þ þ þ þ
DMR-3 2,774 NE NE þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ   
TFBS enrichment of total
DMRs versus whole
genome
7,890 13.25 3.84 17.26 15.99 17.26 18.65 13.25 18.65 13.25 17.26 18.65 13.25 17.26 13.25 17.26 18.65 13.25 17.26
DMR, differentially methylated region; TFBS, transcription factor-binding sites.
Fold enrichment versus total DMRs: o0.75rNE (not enriched) r1.25rþo1.5rþ þo1.75rþ þ þ .
0
50
0
100
0
100
0
150
0
200
0
500
0
500
0
2,000
H3K27me3
difference
H3K4me3
difference
TF
 
e
xp
re
ss
io
n
 
(F
PK
M)
Average
TFBS
methylation
difference 
OCT4
n= 3,761
SOX2
n= 4,526
KLF4
n= 10,875
NANOG
n= 10,343
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
TF
 
e
xp
re
ss
io
n
(F
PK
M)
TF
 
e
xp
re
ss
io
n
(F
PK
M)
 
ESRRB
n= 21,647
TCFCP2L1
n=26,910 
SUZ12
n= 4,215
EZH2
n= 5,185
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2°
M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2M
EF
D
2H
D
5H
D
8H
D
11
H
D
16
H
D
18
H
D
16
L
D
21
L
D
21
Ø
1i
PS
C
2i
PS
C
ES
C
2°
M
EF
D
2
D
5
D
8
D
11
D
16
D
18 D
16
L
D
21
L
D
21
Ø
1°
iP
SC
2°
iP
SC
ES
C
0
–0.1
–0.2
0.1
0
0.2
0
–0.1
Average
TFBS
methylation
difference
H3K4me3
difference
H3K27me3
difference 
Average
TFBS
methylation
difference 
H3K4me3
difference
H3K27me3
difference 
0.1
0
0.2
0
–0.1
0
–0.1
0.1
0
–0.1
0
–0.1
0.1
0
0.1
Figure 3 | Histone modiﬁcation and DNA methylation change at transcription factor-binding sites. RNA expression level (FPKM) of transcription factors
(line plots), average DNA methylation change (upper bar plots), average H3K4me3 change (blue bar plots) and average H3K27me3 change (red bar
plots) at binding sites of each transcription factor. Selected transcriptionally active genes during high-dox treatment (blue box), transcriptionally silent
genes during high-dox treatment (green box) and polycomb repressive complexes (red box) are shown.
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TFBSs and histone modiﬁcation are enriched in the DMRs. To
assay the distribution of histone marks, we performed ChIP-Seq
for H3K4me3, H3K27me3 and H3K36me3 (see Methods). We
determined the distribution and enrichment of these histone
marks within DMRs, as well as other genomic features including
ESC-TFBSs from published data23–26 (Supplementary Data 3).
Notably, we found that 98% of DMRs contained H3K4me3
clusters and 68% contained ESC-TFBSs (Fig. 2d). When we
assessed enrichment of each feature relative to the whole genome,
H3K4me3 marks, ESC-TFBSs, CpG islands, CpG shores and
enhancers showed more than 10-fold enrichment, followed by
promoters and H3K27me3 clusters (Fig. 2e).
Our ﬁnding that histone marks were highly enriched within
DMRs led us to explore the relationship between DNA
methylation levels and H3K4me3/H3K27me3 marks within
DMRs (Fig. 2f, Supplementary Fig. 2c, Supplementary Table 1).
DMRs exhibiting low-level methylation (less than 30%) were
frequently associated (96.9%) with H3K4me3 and H3K27me3. In
contrast, the absence of both histone marks was most frequently
associated (79.7%) with DMRs with high levels of methylation
(Z70%), supporting the inverse relationship between DNA
methylation and these two histone modiﬁcations. Furthermore,
CpGs inside H3K4me3 and H3K27me3 marks exhibit more
methylation change, in comparison with CpGs inside H3K36me3
mark (Supplementary Fig. 2d).
To investigate the involvement of ESC-TFBSs in reprogram-
ming, we performed separate enrichment analysis for each DMR
group (Table 1). Polycomb-repressive complex (PRC)-binding
sites, including SUZ12, EZH2 and RING1B, were enriched in
DMR-1 and DMR-2b. On the other hand, sequence-speciﬁc
pluripotency-associated ESC-TFBSs such as Nanog, Oct4 and
Klf4 (but not CTCF and TET1)-binding sites were enriched in
DMR-3, the group of DMRs that are demethylated only in the
ESC-like state. These results demonstrate the dynamic changes in
DNA methylation at TFBSs, and the connection between the
pattern of changes and TFBS enrichment.
Dynamic changes of TFBS methylation during reprogram-
ming. Interrogating methylation changes at ESC-TFBSs resulted
in the detection of methylation depletion during high-dox treat-
ment, which was not apparent by examining DMRs (Fig. 3,
Supplementary Fig. 3; Methods). This was most obvious at the
binding sites for activated or overexpressed transcription factors
during early time points, such as OCT4, SOX2, KLF4 and
NANOG. These TFBSs also accumulated H3K4me3 modiﬁca-
tions that proceed after the methylation depletion. H3K27me3
marks diminished at binding sites of expressed transcription
factors early in reprogramming. In contrast, ESC-TFBSs for genes
that were not activated during high-dox reprogramming but are
known to play critical roles in ESC-like pluripotent state, such as
ESRRB and TCFCP2L1 (refs 14,27,28), showed no change in
DNA methylation and were demethylated only in the ESC-like
state. The PRC (SUZ12 and EZH2)-binding sites underwent a
gain of DNA methylation during reprogramming but showed
baseline levels of methylation in ESC.
We assessed DNA methylation changes occurring within
±40 kb of ESC-TFBSs (Fig. 4, Supplementary Fig. 4). At the
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Figure 4 | Histone modiﬁcation and DNA methylation change around transcription factor-binding sites. Average DNA methylation change (left),
average H3K4me3 change (middle) and average H3K27me3 change (right) in the 80-kb neighbourhood of transcription factor-binding sites.
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Figure 5 | Epigenetic features of gene classes and model of gene expression control. (a) Genes were separated into clusters based on gene expression
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binding sites of core ESC-pluripotency transcription factors
(OCT4, SOX2, KLF4 and NANOG), we observed rapid focal
demethylation during high-dox treatment (D2H-D18H) if the
factors were expressed. On the other hand, ESC-like cells (1iPSC,
2iPSC and ESC) exhibited extensive demethylation, up to 20 kb
distal from the binding sites. A similar but more delayed process
was also observed for H3K4me3 modiﬁcations. The broad
neighbourhoods around PRC-binding sites were hypermethylated
in all samples examined. Interestingly, although methylation
accumulated broadly around PRC (SUZ12, EZH2 and RING1B)-
binding sites (Fig. 4, Supplementary Fig. 4), these underwent
focal renormalization at the ESC-like pluripotent state. These sites
also demonstrate bivalent marks of H3K4me3 and H3K27me3
in ESC-like state24. The patterns of change to DNA methylation
and histone marks were distinct for the three types of
transcription factor shown (Figs 3 and 4). Our results show an
interesting contrast between the focal demethylation induced
early in reprogramming and broader demethylated regions at
ESC-like pluripotent state, perhaps representing a key
distinguishing feature of the pluripotent state where broader
demethylation is required for completion of the reprogramming
to ESC-like state.
We attempted to show that the dynamics of methylation
change at transcription factor-binding sites (TFBSs) could act as a
predictor of importance to the reprogramming process. We
proposed criteria for DNA-binding transcription factors of
41.2 enrichment and 410% overlap in DMR-3, implying
over-representation in DMRs that underwent demethylation at
transition to the ESC-like state, but little change early in
reprogramming. We tested a set of 118 transcription factors with
computationally predicted binding sites against these criteria29,30.
We found only three transcription factors (SOX2, MYC and
OCT4) that fulﬁlled our criteria, all of which are known to be
important in reprogramming to iPSCs (Supplementary Data 4).
This suggests a high speciﬁcity for the prediction criteria,
although sensitivity is low as other factors known to be
involved in reprogramming were not identiﬁed. Transcription
factors whose binding sites show signiﬁcant change in
methylation late in a transition can be called important to that
transition with high conﬁdence. We believe that methylome-
based tests of this nature could have useful application in
prediction of transcription factors involved in other cellular
transitions.
Demethylation leads to precise control of gene expression. We
integrated corresponding RNA expression data22 with our DNA
methylation and histone modiﬁcation data sets (Supplementary
Tables 2–4, Supplementary Data 5; Methods). Activation of
genes was associated with H3K4me3 occupancy in promoter
regions and repression was associated with either H3K27me3
occupancy or no histone mark (Supplementary Fig. 5a).
Moreover, as we observed in DMRs, engagement of both
H3K4me3 and H3K27me3 marks in promoters was dependent
on DNA methylation levels with a strong inverse relationship
(Supplementary Fig. 5b).
We selected 477 genes segregating into seven clusters on the
basis of expression and epigenetic change over the course of
reprogramming (Fig. 5a,b, Supplementary Table 5; Methods).
These groups represent: activated early in reprogramming (Expr-
1a), activated late in reprogramming with either low- (Expr-1b)
or full- (Expr-1c) DNA methylation in 2MEF and repressed
during reprogramming with either low- (Expr-2a) or full-
(Expr-2b) DNA methylation in ESC. Genes in Expr-3a were
turned on, while those in Expr-3b were turned off in high-dox;
therefore, they were differentially expressed between D16H/D18H
(F-class cells) and ESC-like cells. Expression changes of genes in
Expr-1a and Expr-2a/b are likely responsible for pluripotency, as
they were differentially expressed between 2MEF and pluripo-
tent cells21. Finally, the presence of genes in Expr-1b/c explains
why F-class cells are distinct from ESC-like state cells.
The expression dynamics through reprogramming of these
genes was clear upon visualization of the categories and
representative genes from each class (Fig. 5a,b, Supplementary
Fig. 5a–d). Genes repressed by H3K27me3 with low-methylated
promoters in 2MEF tended to be activated early in reprogram-
ming and had CpG-rich promoters (Expr-1a/b). These loci were
enriched in genes involved in cell adhesion, such as Epcam and
Cdh1 (Fig. 5a (Expr-1a)). In contrast, quiescence of Expr-1c genes
was initially safeguarded by DNA methylation of CpG-poor
promoters, and H3K4me3 was only acquired after late demethy-
lation. The same two modes of control were observed for the
genes repressed by reprogramming. However, as in the analysis of
DMRs, DNA methylation in promoter regions happened early in
reprogramming (Expr-2b), whereas demethylation was detected
exclusively in the ESC-like state, revealing that a gain of
methylation is kinetically favoured over demethylation. This is
also true for histone marks in relation to changes in gene
expression, where histone modiﬁcations, speciﬁcally the modula-
tion of H3K27me3, occurred early during reprogramming
(Expr-2a) within low-methylated promoters. Interestingly, the
dynamic process of histone modiﬁcation alterations during
reprogramming was strongly inﬂuenced by the starting methyla-
tion state of gene promoters (Fig. 5c,d). Genes with low-
methylated promoters at 2MEF showed a signiﬁcantly higher
rate of transition to the ESC-like state for both ESC-speciﬁc
histone marks compared with those with fully methylated
promoters. This suggests that DNA methylation presents a major
barrier during somatic cell reprogramming to ESC-like cells and
that the methylation status of a given region determines its
control by histone modiﬁcations.
We propose a model that describes the key mechanism of
epigenetic control of gene expression during reprogramming
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(Fig. 6). In genes with CpG-poor promoters, control is driven by
DNA methylation. Such genes may be activated by demethylation
followed by H3K4me3 engagement, producing expression proﬁles
characteristic of class Expr-1c/2b. In genes with CpG-rich
promoters, low methylation levels allow histone modiﬁcation-
driven control. This model is supported by data showing the role
of initial methylation status as a modulator of the dynamic
changes to histone modiﬁcation, and the sequential modiﬁcation
of DNA methylation followed by histone marks in TFBSs. The
model also accounts for characteristic gene expression classes
(detailed in Figs 5 and 6). We predict that this mechanism may
not only apply to iPSC reprogramming but also to lineage
speciﬁcation of cells. Therefore, our insights into how DNA
methylation controls the epigenetic landscape in reprogramming
to pluripotency could be crucial to a better understanding of the
mechanisms underlying general cell fate change, and could have
ramiﬁcations for stem cell-based therapies.
Methods
Cell culture and secondary reprogramming. ROSA26-rtTA-IRES-GFP mouse
ESC, iPSCs and mouse embryonic ﬁbroblasts were cultured as previously descri-
bed31. ESCs and iPSCs were cultured in 5% CO2 at 37 C on irradiated MEFs in
DMEM containing 15% FCS, leukaemia-inhibiting factor, penicillin/streptomycin,
L-glutamine, nonessential amino acids, sodium pyruvate and 2-mercaptoethanol.
1B 1 iPS cells were aggregated with tetraploid host embryos as described10 and
MEFs established from E13.5 embryos. High-dox cell samples were collected on
days 0, 2, 5, 8, 11, 16 and 18 (D2H, D5H, D8H, D11H, D16H and D18H). A
subculture of the reprogramming cells was established from day 19 and cultured in
the absence of dox, to develop a factor-independent 2 iPS cell line by day 30
(2iPSC). Low-dox samples were maintained from day 8 to day 14 cells in 5 ng dox.
On day 14 the culture was diverged into two, with some of the cells being cultured
until day 21 in the absence of dox (D21Ø) and the remainder being cultured in
5 ngml 1 of dox and collected on day 16 (D16L) and (D21L). Rosa26rtTA ESCs
and 1B 1o iPSCs were collected as controls.
MethylC-Seq library generation. For all 13 samples (2MEF, D2H, D5H, D8H,
D11H, D16H, D18H, D16L, D21L, D21Ø, 1iPSC, 2iPSC and rtTA ESC), 5mg of
genomic DNA was mixed with 25 ng unmethylated cl857 Sam7 Lambda DNA
(Promega, Madison, WI, USA). The DNA was fragmented by sonication to
300–500 bp with a Covaris S2 system (Covaris) followed by end repair with the
End-It DNA End-Repair Kit (Epicenter). Paired-end universal library adaptors
provided by Illumina were ligated to the sonicated DNA as per the manufacturer’s
instructions for genomic DNA library construction. Ligated products were puriﬁed
with AMPure XP beads (Beckman, Brea, CA, USA). Adaptor-ligated DNA was
bisulﬁte-treated using the EpiTect Bisulﬁte Kit (QIAGEN) following the manu-
facturer’s instructions and then PCR-ampliﬁed using PfuTurboCx Hotstart DNA
polymerase (Agilent, Santa Clara, CA, USA) with the following PCR conditions
(2min at 95 C, 4 cycles of 15 s at 98 C, 30 s at 60 C, 4min at 72 C and then
10min at 72 C). The reaction products were puriﬁed using the MinElute gel
puriﬁcation kit (QIAGEN). The sodium bisulﬁte non-conversion rate was
calculated as the percentage of cytosines sequenced at cytosine reference positions
in the lambda genome.
ChIP library generation. ChIP was carried out as described in ref. 32. In all,
40–150 million cells were ﬁxed with 1% formaldehyde for 10min at room
temperature, and scraped and stored as pellets ( 80 C). Samples were lysed at
20 million cells per ml Farnham lysis buffer for 10min and subsequently at
10 million cells per ml nuclear lysis buffer. The released chromatin was sheared to
100–500 bp (250 bp average) on ice using a SonicsVibraCell Sonicator equipped
with a 3-mm probe. For each sample, 50 ml of solubilized chromatin was used as
input DNA to normalize sequencing results and the remaining chromatin was
immunoprecipitated with 10 mg of H3K4me3 (ab8580)33, 10 mg H3K27me3
(Millipore 07-449)16 or 10 mg H3K36me3 (ab9050)16 antibodies, separately.
Antibody–chromatin complexes were pulled down with 100ml magnetic Protein G
Dynal beads (Invitrogen) and washed six times. The chromatin was then eluted,
reverse crosslinked at 65 C overnight and subjected to RNaseA/proteinase K
treatment. ChIP and input DNA were puriﬁed using a Qiagen Puriﬁcation Column
and quantiﬁed using a Quant-it dsDNA High Sensitivity Assay (Invitrogen). For
ChIP sequencing, ChIP-seq libraries were prepared according to the protocols
described in the Illumina ChIP-seq library preparation kit. Brieﬂy, 50 ng of
immunopuriﬁed DNA or 100 ng of genomic DNA from an input sample was end-
repaired, followed by the 30 addition of a single adenosine nucleotide and ligation
to universal library adapters. Ligated material was separated on a 2.0% agarose gel,
followed by the excision of a 250- to 350-bp fragment and column puriﬁcation
(QIAGEN). DNA libraries were prepared by PCR ampliﬁcation (18 cycles).
High-throughput sequencing. MethylC-Seq DNA and ChIP DNA libraries were
sequenced using the Illumina HiSeq 2000 as per the manufacturer’s instructions.
Sequencing of libraries was performed up to 2 101 cycles. Image analysis and
base calling were performed with the standard Illumina pipeline version RTA 2.8.0.
Processing and alignment of MethylC-Seq data. MethylC-Seq sequencing data
were processed using the Illumina analysis pipeline, and FastQ format reads were
aligned to the NCBI37/mm9 mouse reference using the Bismark/Bowtie alignment
algorithm18,34,35. Paired-read MethylC-Seq sequences produced by the Illumina
pipeline in FastQ format were trimmed with trim threshold 1,500; we removed the
last two bases from sequences that were not trimmed and removed three bases
from sequences that were trimmed. The Bismark package version 0.7.7 was used as
the aligner using the following parameters: -e 90 -n 2 -l 32 -X 550. As up to six
independent libraries from each biological replicate were sequenced, we ﬁrst
removed duplicate reads. Subsequently, the reads from all libraries of a particular
sample were combined. Unique read alignments were then subjected to post-
processing. The number of calls for each base at every reference sequence position
and on each strand was calculated. All results of aligning a read to both the Watson
and Crick converted genome sequences were combined. The CpG methylation
levels were calculated using bisulﬁte conversion rates by (Number of not converted
Cs per read depth) for each position (Supplementary Data 1).
RNA-Seq library generation and sequencing. Total RNA was subjected to two
rounds of on column DNAseI treatment to remove contaminating DNA using the
RNase-Free DNase set (Qiagen PN 79254) as per the manufacturer’s protocol. The
total RNA was then analysed using the Agilent RNA 6000 Nano Kit (PN 5067-
1511) on the Agilent Bioanalyzer 2100 (PN G2939AA) to quantify yield, qualify
integrity and conﬁrm removal of DNA contamination.
Following DNAseI treatment, 5 mg total RNA from each sample was depleted
of ribosomal RNA using the Ribo-ZerorRNA Removal Kit (Epicenter PN
RZH110424) as per the manufacturer’s instructions. The ribosomal-depleted RNAs
were then run on an Agilent RNA 6000 Pico Kit (PN 5067-1513) on the Agilent
Bioanalyzer 2100 to conﬁrm ribosomal RNA depletion. Sequencing libraries where
generated from the ribosomal-depleted RNA using the SOLiD Transcriptome
Multiplexing Kit (PN 4427046) from Applied Biosystems following the
manufacturer’s publication. Final libraries were quantiﬁed and qualiﬁed using the
Agilent High Sensitivity DNA Kit (PN 5067-4626) on the Agilent Bioanalyzer 2100.
Sequencing libraries were subsequently pooled in equimolar ratios (four
libraries per pool) and clonally ampliﬁed on SOLiD nanobeads. Clonal
ampliﬁcation was completed via emulsion PCR using the SOLiD EZ Bead System
(PN 4448419, 4448418 and 4448420) coupled with SOLiD EZ Bead N200
ampliﬁcation reagents (PN 4467267, 4457185, 4467281, 4467283 and 4467282).
Following emulsion PCR, clonally ampliﬁed nanobeads were enriched using the
SOLiD EZ Bead Enricher Kits (PN 4467276, 4444140 and 4453073) before being
deposited into SOLiD 6-Lane FlowChip (PN 4461826) using the SOLiD Flowchip
Deposition Kit v2 (PN 4468081) as per the manufacturer’s recommendations.
In total, two ﬂowchips were sequenced yielding a total of eight lanes of data,
with sequencing reads generated using the SOLiD 5500xl platform generating
paired 75 bp forward and 35 bp reverse reads. To allow de-convolution of the
pooled libraries, a single 5-bp index read was generated. A total of 1,204,676,394
fragments (2,409,352,788 reads) were generated post deconvolution, ranging from
35,714,748 to 147,282,580 fragments per library.
Processing and alignment of RNA-Seq data. Sequence mapping was performed
using Applied Biosystems LifeScope v2.5 whole transcriptome (paired-end) ana-
lysis pipeline against the NCBIM37 (mm9) genome and exon-junction libraries
constructed from the Ensembl v64 gene model. Brieﬂy, this pipeline ﬁrst removes
potential contaminant reads by aligning to a ﬁlter set containing rRNA, tRNA,
adaptor sequences and retrotransposon sequences. Following ﬁltering, LifeScope
then aligns all reads to the genome and F3 reads to the junction library. F5 reads
are additionally aligned at a higher sensitivity to exonic sequences within insert size
distance from the paired (F3) read alignment. Read alignments are merged and
disambiguated, and a single BAM (binary alignment/mapped) ﬁle output per
library.
BAM ﬁles were then additionally ﬁltered to remove reads with a mapping
quality (MAPQ)o9 and all mitochondrial reads. Alignments were then assembled
using Cufﬂinks (v2.0.2) using the –G parameter to quantify gene and isoform
FPKM expression values against the reference gene model (Ensembl v67).
Identiﬁcation of methylated cytosines. At each reference cytosine, the binomial
distribution was used to identify whether at least a subset of the genomes within the
sample were methylated, using a 0.01 FDR-corrected P value. We identiﬁed methyl
cytosines while keeping the number of false-positive methylcytosine calls below 1%
of the total number of methyl cytosines we identiﬁed. The probability P in the
binomial distribution B(n, P) was estimated from the number of cytosine bases
sequenced in reference cytosine positions in the unmethylated Lambda genome
(referred to as the error rate: nonconversion plus sequencing error frequency). We
interrogated the sequenced bases at each reference cytosine position one at a time,
where read depth refers to the number of reads covering that position. For each
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position, the number of trials (n) in the binomial distribution was the read depth.
For each possible value of n we calculated the number of cytosines sequenced (k) at
which the probability of sequencing k cytosines out of n trials with an error rate of
p was less than the valueM, whereM* (number of unmethylated cytosines)o0.01*
(number of methylated cytosines) and if the error rate of p was over 0.01, we
assumed that the cytosine was not methylated. In this way, we established the
minimum threshold number of cytosines sequenced at each reference cytosine
position at which the position could be called as methylated, so that out of all
methyl cytosines identiﬁed no more than 1% would be because of the error rate.
Calculation of DNA methylation level. If the error rate is less than 0.01 we
calculated adjusted DNA methylation level for cytosine as follow:
Adjusted cytosinemethylation level ¼ a
b
cr
  
a
ð1Þ
(a¼ total Cs, b¼ number of converted Cs, cr¼ bisulﬁte conversion rate).
Identiﬁcation of DMRs. DMRs (Fig. 2) were identiﬁed using a sliding window
approach (Supplementary Fig. 6a, Fig. 2b). A window size of 30 CpGs less than 6 kb
with coverage more than 5 in 15 CpGs per window in all samples were con-
sidered, progressing one CpG per iteration. Total of 20,214,978 windows were
assessed. Windows showing maximum difference and fold enrichment of 30% and
fourfold with Benjamini–Hochberg-corrected FDR from analysis of variance
(ANOVA) test P values of less than 1% were identiﬁed as differentially methylated
windows. In all, 188,529 differentially methylated windows were then joined if
regions were overlapped or progressing region and the succeeding regions were
covering more than 60% of the region. This set of 7,890 DMRs covering
21,618,964 bp of the whole genome are reported in Fig. 2 and Supplementary Data 2.
DMRs were then deﬁned as Hyper-DMRs and Hypo-DMRs if the average
methylation level difference of each DMR in each sample was higher or lower by
more than 20% relative to 2MEF.
Mapping and enrichment analysis of ChIP-Seq reads. Paired-end ChIP-Seq
data were processed using the Illumina analysis pipeline, and mapping was con-
ducted using Bowtie version 0.12.8 with the following parameters: --pairtries 100 -y
-k 1 -n 3 -l 50 -I 0 -X 1000. Enrichment analysis was conducted using MACS36
with parameters of --nomodel -S -w –n –space 30.
ChIP-Seq data analysis. Enriched peaks from ChIP-Seq data were joined into
clusters where at least one sample has a peak for each modiﬁcation (H3K4me3,
H3K27me3 and H3K36me3; Supplementary Fig. 6b). The total peak width of each
sample within the cluster was calculated as histone mark score within clusters.
TFBS epigenomic change analysis. ESC-TFBSs of mouse ESCs were obtained
from different studies23–25. CpG methylation level of each TFBS in each sample
was calculated. The average CpG methylation change of each TFBS was than
calculated in each sample relative to 2MEF (Fig. 3). For calculating CpG
methylation change around ESC-TFBSs, the same procedure was applied for 200 bp
400 bins around each ESC-TFBS. The same procedure using enrichment score for
30-bp window was applied for calculating average histone modiﬁcation change
(Fig. 4).
Genome annotation. Genomic regions and CpG islands were deﬁned based on
NCBI37/mm9 coordinates downloaded from the UCSC website (http://geno-
me.ucsc.edu/). Promoters were arbitrarily deﬁned as 5 kb upstream and 1 kb
downstream of transcriptional start site for each Ensembl release-67 transcript.
Gene bodies are deﬁned as from transcription start to end sites for each transcript.
Histone modiﬁcation clusters and DMRs were annotated if they overlap with their
promoters.
Fold-enrichment test. Fold enrichment was calculated as follows: (Observed
number of X in examining region/total length of examining region (bp))/(total
number of X in reference region/reference region length (bp)), X¼ genomic
feature)).
Gene expression pattern separation. We selected genes of expression patterns as
described in Supplementary Table 5.
Data integration and normalization. DNA methylation levels of promoters were
calculated from 5 kb upstream and 1 kb downstream of the transcription start site.
H3K4me3 and H3K27me3 marks were considered if their cluster of peaks were
overlapped with promoters. Overlapped H3K36me3 peaks were calculated for
whole gene. In Fig. 5, for calculating normalized histone modiﬁcation scores,
maximum peak width was considered as 1 and relative widths were calculated for
each sample in each gene.
Accession codes. Methylome sequencing data are available under the European
Nucleotide Archive accessions no. ERP004116 (http://www.ebi.ac.uk/ena/data/
view/PRJEB4795). Long RNA-seq and Chip-seq sequencing data are available
under the NCBI Sequence Read Archive (SRA) accessions no. SRP046744 (http://
www.ncbi.nlm.nih.gov/sra). Analysed data sets can be obtained from Stemfor-
matics (www.stemformatics.org)37.
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